touchPODCAST

touchpodcast

Welcome to touchPODCAST where you can listen and learn from our expert faculty, hand-picked from the Touch Medical Media family of independent medical websites. Educating physicians on a fully global scale since 2005! We make positive changes to clinical practice, with the ultimate objective of improving patient and community health. Working alongside leading medical experts, societies and industry, our mission is to provide practical, expert opinions to support best practices for busy Healthcare Professionals globally, by translating published data into easily digestible and timely updates Home of: - touchONCOLOGY - touchENDOCRINOLOGY - touchOPHTHALMOLOGY - touchNEUROLOGY - touchCARDIOLOGY - touchINFECTIOUSDISEASES - touchIMMUNOLOGY - touchRESPIRATORY - touchHAEMATOLOGY - touchDERMATOLOGY This information is intended for use by licensed Healthcare Professionals (HCPs). It should not be considered medical advice, diagnosis, or treatment recommendations.

  1. 2d ago

    Treatment selection after EGFR-TKI therapy: Matching biology to strategy

    touchCLINICAL PERSPECTIVES for touchONCOLOGY and touchRESPIRATORY Module 1: MET-driven progression: Targeting the bypass In this module, medical oncologist Dr. Julia Rotow explores the biological rationale and emerging clinical evidence behind MET amplification and overexpression as drivers of resistance following EGFR-TKI therapy in non-small cell lung cancer (NSCLC). Together with molecular pathologist Dr. Umberto Malapelle, they compare tissue and liquid biopsy approaches, including diagnostic cut-offs and thresholds used. Finally, in discussion with nurse practitioner Ms. Cathleen Power, the experts use a patient case to provide guidance on MET-directed therapy selection for patients who experience disease progression on EGFR-TKIs, managing treatment-related adverse events, and dosing considerations. Course director: Dr. Julia Rotow, Dana-Farber Cancer Institute, Boston, MA, USA The experts: Dr. Umberto Malapelle, University of Naples Federico II, Italy Ms. Cathleen Power, Dana-Farber Cancer Institute, Boston, MA, USA Module 2: Progression or evolution? Navigating the post–EGFR-TKI landscape  Coming soon Module 3: When actionable resistance biology is unclear: Sequencing treatment strategies after EGFR-TKI therapy Coming soon Patient cases in this activity are hypothetical and are presented for educational purposes only. This touchPODCAST is for healthcare professionals globally, outside of the UK. This activity is funded by an independent medical education grant from AstraZeneca. This activity is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider. For further information and to claim your CME credit, visit our websites: https://touchONCOLOGYime.org/ or https://touchRESPIRATORYime.org/

About

Welcome to touchPODCAST where you can listen and learn from our expert faculty, hand-picked from the Touch Medical Media family of independent medical websites. Educating physicians on a fully global scale since 2005! We make positive changes to clinical practice, with the ultimate objective of improving patient and community health. Working alongside leading medical experts, societies and industry, our mission is to provide practical, expert opinions to support best practices for busy Healthcare Professionals globally, by translating published data into easily digestible and timely updates Home of: - touchONCOLOGY - touchENDOCRINOLOGY - touchOPHTHALMOLOGY - touchNEUROLOGY - touchCARDIOLOGY - touchINFECTIOUSDISEASES - touchIMMUNOLOGY - touchRESPIRATORY - touchHAEMATOLOGY - touchDERMATOLOGY This information is intended for use by licensed Healthcare Professionals (HCPs). It should not be considered medical advice, diagnosis, or treatment recommendations.

You Might Also Like